skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Update on ropinirole in the treatment of Parkinson’s disease

Review

(4584) Views  (1005) Full article downloads

Authors: Holly A Shill, Mark Stacy

Published Date December 2008 Volume 2009:5 Pages 33 - 36
DOI: http://dx.doi.org/10.2147/NDT.S3237

Holly A Shill, Mark Stacy

Sun Health Research Institute, Sun City, AZ, USA; Duke University and Medical Center, Durham, NC, USA

Abstract: Ropinirole is a dopamine agonist, approved for use to treat symptoms of early and advanced Parkinson’s disease, is now available in a 24-hour formulation in addition to the immediate release version. This review discusses the mode of action of ropinirole and compares the pharmacokinetics of both formulations. Pivotal studies leading to the approval of both preparations are reviewed in terms of efficacy, dose range and side effects. Patient factors such as compliance are discussed in terms of the place for ropinirole in the armamentarium of Parkinson’s disease therapies.

Keywords: ropinirole extended release, ropinirole immediate release Parkinson’s disease






 

Other articles by Professor Mark Stacy



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Coenzyme Q10 effects in neurodegenerative disease
Ropinirole in restless legs syndrome and periodic limb movement disorder
Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update
Relationship between esomeprazole dose and timing to heartburn resolution in selected patients with gastroesophageal reflux disease
Retinal nerve fiber layer thickness in recovered and persistent amblyopia
Erratum - Intracellular heavy metal nanoparticle storage
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Primary care for diabetes mellitus: perspective from older patients
Evaluating the effects of crystallinity in new biocompatible polyester nanocarriers on drug release behavior